Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREATALL: Emtricitabine–Tenofovir in Real‑World Chronic Hepatitis B Patients with Comorbidities
ChiCTR2600126470Phase 4Not yet recruiting
- Sponsor
- The Third Hospital of Hebei Medical University
- Start
- Jun 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, open-label trial of emtricitabine + tenofovir disoproxil in Chronic Hepatitis B (CHB), chronic kidney disease (CKD), Cirrhosis and 1 more (4 cohorts), sponsored by The Third Hospital of Hebei Medical University. Primary endpoint: Complete virological response rate of each cohort at 48 weeks. Planned start Jun 2026; status: not yet recruiting.
02
Drugs
emtricitabine + tenofovir disoproxil
03
Conditions
Chronic Hepatitis B (CHB)chronic kidney disease (CKD)Cirrhosiscardiometabolic risk (CMR)
Beyond the preview
Go deeper on ChiCTR2600126470.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600126470.